NASDAQ:GHDXGenomic Health Stock Price, Forecast & News Notice: This company has been marked as potentially delisted and may not be actively trading. Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Genomic Health, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $63.44 0.00 (0.00 %) (As of 11/8/2019) Add Compare Share Today's Range$63.44Now: $63.44▼$63.4450-Day Range$63.44MA: $64.79▼$69.7952-Week Range$50.77Now: $63.44▼$90.18VolumeN/AAverage Volume1.05 million shsMarket Capitalization$2.38 billionP/E Ratio60.42Dividend YieldN/ABeta0.9 ProfileAnalyst RatingsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Genomic Health, Inc., a healthcare company, provides clinically actionable genomic information to personalize cancer treatment decisions in the United States and internationally. The company develops and commercializes genomic-based clinical laboratory services that analyze the underlying biology of cancer, which allows physicians and patients to make individualized treatment decisions. It offers the Oncotype DX invasive breast cancer test that is used for early stage invasive breast cancer patients to predict the breast cancer recurrence and chemotherapy benefit. The company also provides the Oncotype DX colon cancer test, which is used to predict the likelihood of colon cancer recurrence in patients with stage II disease, as well as for use in patients with stage III disease treated with oxaliplatin-containing adjuvant therapy; Oncotype DX prostate cancer test, which provides a genomic prostate score to predict disease aggressiveness in men with low risk prostate cancer, as well as to enhance treatment decisions for prostate cancer patients in conjunction with the Gleason score; and Oncotype DX AR-V7 nucleus detect tests for men with metastatic castration-resistant prostate cancer. In addition, it develops Oncoytpe DXi IVD breast recurrence score test; and Oncotype DX GPS test. The company offers its products through a network of distributors. Genomic Health, Inc. has license and development agreement with Biocartis N.V. to develop and commercialize an in vitro diagnostic of the Oncotype DX breast cancer test; collaboration agreement with Epic Sciences, Inc. to commercializeAR-V7 Nucleus Detect test; and license and development agreement with Cleveland Diagnostics, Inc. to develop and commercialize new prostate cancer tests. The company was founded in 2000 and is based in Redwood City, California.Read More Beat the Market (BTM) Rank™ 2.0 Analyst's Opinion Consensus RatingGenomic Health has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 5 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $71.40, Genomic Health has a potential upside of 12.5% from its current price of $63.44.Amount of Analyst CoverageGenomic Health has received no research coverage in the past 90 days. Previous Next 2.3 Community Rank Outperform VotesGenomic Health has received 341 “outperform” votes. (Add your “outperform” vote.)Underperform VotesGenomic Health has received 392 “underperform” votes. (Add your “underperform” vote.)Community SentimentGenomic Health has received 53.48% “underperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Genomic Health and other stocks. Vote “Outperform” if you believe GHDX will outperform the S&P 500 over the long term. Vote “Underperform” if you believe GHDX will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldGenomic Health does not currently pay a dividend.Dividend GrowthGenomic Health does not have a long track record of dividend growth. Previous Next 1.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Genomic Health insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 31.30% of the stock of Genomic Health is held by insiders.Percentage Held by Institutions93.87% of the stock of Genomic Health is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Genomic Health are expected to grow by 8.86% in the coming year, from $1.58 to $1.72 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Genomic Health is 60.42, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 13.45.Price to Earnings Ratio vs. SectorThe P/E ratio of Genomic Health is 60.42, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 16.25.Price to Book Value per Share RatioGenomic Health has a P/B Ratio of 8.48. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 2.0Community Rank: 2.3Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.19 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Medical laboratories Sub-IndustryBiotechnology SectorMedical Current SymbolNASDAQ:GHDX Previous Symbol CUSIP37244C10 CIK1131324 Webwww.genomichealth.com Phone650-556-9300Debt Debt-to-Equity Ratio0.15 Current Ratio5.96 Quick Ratio5.96Price-To-Earnings Trailing P/E Ratio60.42 Forward P/E Ratio40.15 P/E GrowthN/A Sales & Book Value Annual Sales$394.11 million Price / Sales6.05 Cash Flow$1.45 per share Price / Cash Flow43.76 Book Value$7.48 per share Price / Book8.48Profitability EPS (Most Recent Fiscal Year)$1.05 Net Income$25.68 million Net Margins12.81% Return on Equity19.62% Return on Assets14.89%Miscellaneous Employees829 Outstanding Shares37,590,000Market Cap$2.38 billion Next Earnings DateN/A OptionableOptionable Receive GHDX News and Ratings via Email Sign-up to receive the latest news and ratings for GHDX and its competitors with MarketBeat's FREE daily newsletter. Genomic Health (NASDAQ:GHDX) Frequently Asked Questions Do Wall Street analysts recommend investors buy shares of Genomic Health? 5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Genomic Health in the last year. There are currently 5 hold ratings for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for Genomic Health. How were Genomic Health's earnings last quarter? Genomic Health, Inc. (NASDAQ:GHDX) issued its earnings results on Monday, November, 11th. The medical research company reported $0.48 EPS for the quarter, topping the Thomson Reuters' consensus estimate of $0.37 by $0.11. Genomic Health had a return on equity of 19.62% and a net margin of 12.81%. View Genomic Health's earnings history. What price target have analysts set for GHDX? 5 equities research analysts have issued 12 month price objectives for Genomic Health's shares. Their forecasts range from $69.00 to $72.00. On average, they expect Genomic Health's stock price to reach $71.40 in the next twelve months. This suggests a possible upside of 12.5% from the stock's current price. View analysts' price targets for Genomic Health. What are Wall Street analysts saying about Genomic Health stock? Here are some recent quotes from research analysts about Genomic Health stock: 1. According to Zacks Investment Research, "Over the past year, Genomic Health has been outperforming its industry. The company is registering robust top-line growth banking on solid performance in the United States and internationally. In the last-reported quarter, breast cancer revenues were strong driven by increased Oncotype DX Breast Recurrence Score test usage globally which is amplifying on favorable results from the landmark TAILORx trial. Within the prostate cancer space, the company is seeing robust improvement in volume as the Oncotype DX GPS test consistently leads the market in low- and intermediate-risk prostate cancer test adoption. However, the company’s sole reliance on the Breast Oncotype DX test is a concern. Moreover, the company continues to face fierce competition for Oncotype DX tests." (7/31/2019) 2. Canaccord Genuity analysts commented, "We are also lowering our price target from $77 to the deal price of $72. Our prior $77 PT used a 6.7x multiple on our 2021 revenue estimate of $540M. We note that our peer group (as of today) is trading at 6.7x our 2020 revenue estimates." (7/30/2019) Has Genomic Health been receiving favorable news coverage? Media stories about GHDX stock have trended extremely negative recently, InfoTrie reports. InfoTrie identifies negative and positive press coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Genomic Health earned a media sentiment score of -4.0 on InfoTrie's scale. They also assigned media coverage about the medical research company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the stock's share price in the next several days. View the latest news aboutGenomic Health. Who are some of Genomic Health's key competitors? Some companies that are related to Genomic Health include Amgen (AMGN), Gilead Sciences (GILD), Celgene (CELG), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Biogen (BIIB), Seattle Genetics (SGEN), Alexion Pharmaceuticals (ALXN), Incyte (INCY), BioMarin Pharmaceutical (BMRN), Alnylam Pharmaceuticals (ALNY), EXACT Sciences (EXAS), Neurocrine Biosciences (NBIX), Ionis Pharmaceuticals (IONS) and Immunomedics (IMMU). View all competitors. What other stocks do shareholders of Genomic Health own? Based on aggregate information from My MarketBeat watchlists, some companies that other Genomic Health investors own include Revance Therapeutics (RVNC), Exelixis (EXEL), Horizon Therapeutics (HZNP), Ionis Pharmaceuticals (IONS), NVIDIA (NVDA), Crispr Therapeutics (CRSP), Tandem Diabetes Care (TNDM), Vertex Pharmaceuticals (VRTX), Gilead Sciences (GILD) and Illumina (ILMN). Who are Genomic Health's key executives? Genomic Health's management team includes the following people: Ms. Kimberly J. Popovits, Chairman, CEO & Pres (Age 60)Dr. Steven Shak, Co-Founder & Chief Scientific Officer (Age 68)Mr. G. Bradley Cole, Chief Financial Officer (Age 63)Dr. Frederic G. Pla, Chief Operating Officer (Age 60)Mr. James J. Vaughn, Chief U.S. Commercial Officer (Age 56) What is Genomic Health's stock symbol? Genomic Health trades on the NASDAQ under the ticker symbol "GHDX." What is Genomic Health's stock price today? One share of GHDX stock can currently be purchased for approximately $63.44. How big of a company is Genomic Health? Genomic Health has a market capitalization of $2.38 billion and generates $394.11 million in revenue each year. The medical research company earns $25.68 million in net income (profit) each year or $1.05 on an earnings per share basis. Genomic Health employs 829 workers across the globe. What is Genomic Health's official website? The official website for Genomic Health is www.genomichealth.com. How can I contact Genomic Health? Genomic Health's mailing address is 301 PENOBSCOT DRIVE, REDWOOD CITY CA, 94063. The medical research company can be reached via phone at 650-556-9300 or via email at [email protected] This page was last updated on 5/31/2020 by MarketBeat.com Staff
